{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:31:19Z","timestamp":1790800279568,"version":"4.1.0"},"reference-count":72,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/kmsa5983","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:38:31Z","timestamp":1710999511000},"page":"387-399","source":"Crossref","is-referenced-by-count":41,"title":["Non-alcoholic fatty liver disease: pathogenesis and models"],"prefix":"10.62347","volume":"16","author":[{"given":"Hanxiang","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts 2016; 9: 65-90.","DOI":"10.1159\/000443344"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J and Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"JK","year":"2010","unstructured":"Dowman JK, Tomlinson JW and Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83.","journal-title":"QJM"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.2174\/1570161115666170621082910","article-title":"Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk","volume":"16","author":"Athyros","year":"2018","unstructured":"Athyros VG, Boutari C, Stavropoulos K, Anagnostis P, Imprialos KP, Doumas M and Karagiannis A. Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Curr Vasc Pharmacol 2018; 16: 246-253.","journal-title":"Curr Vasc Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11892-006-0031-x","article-title":"Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver","volume":"6","author":"Boden","year":"2006","unstructured":"Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006; 6: 177-181.","journal-title":"Curr Diab Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MED.0b013e3283293015","article-title":"Nonalcoholic fatty liver disease in type 2 diabetes mellitus","volume":"16","author":"Cusi","year":"2009","unstructured":"Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009; 16: 141-149.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.2337\/diacare.27.8.2057","article-title":"Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis","volume":"27","author":"Medina","year":"2004","unstructured":"Medina J, Fernandez-Salazar LI, Garcia-Buey L and Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-2066.","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/13813450802181047","article-title":"Insulin resistance associated to obesity: the link TNF-alpha","volume":"114","author":"Nieto-Vazquez","year":"2008","unstructured":"Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L and Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 2008; 114: 183-194.","journal-title":"Arch Physiol Biochem"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","unstructured":"Tilg H and Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M and Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048.","journal-title":"Metabolism"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Boucher J, Kleinridders A and Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol 2014; 6: a009191.","DOI":"10.1101\/cshperspect.a009191"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3748\/wjg.14.2474","article-title":"Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment","volume":"14","author":"Schreuder","year":"2008","unstructured":"Schreuder TC, Verwer BJ, van Nieuwkerk CM and Mulder CJ. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008; 14: 2474-2486.","journal-title":"World J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1210\/er.2008-0009","article-title":"Causes and metabolic consequences of fatty liver","volume":"29","author":"Stefan","year":"2008","unstructured":"Stefan N, Kantartzis K and Haring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008; 29: 939-960.","journal-title":"Endocr Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2174\/138161210791208875","article-title":"Insulin resistance in nonalcoholic fatty liver disease","volume":"16","author":"Bugianesi","year":"2010","unstructured":"Bugianesi E, Moscatiello S, Ciaravella MF and Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16: 1941-1951.","journal-title":"Curr Pharm Des"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1111\/j.1572-0241.2006.00848.x","article-title":"The evolving role of leptin and adiponectin in chronic liver diseases","volume":"101","author":"Tsochatzis","year":"2006","unstructured":"Tsochatzis E, Papatheodoridis GV and Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101: 2629-2640.","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1053\/j.gastro.2003.08.029","article-title":"Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin","volume":"125","author":"Kamada","year":"2003","unstructured":"Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T and Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-1807.","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/hep.21991","article-title":"High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase","volume":"47","author":"Adachi","year":"2008","unstructured":"Adachi M and Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 2008; 47: 677-685.","journal-title":"Hepatology"},{"key":"ref18","unstructured":"Buechler C, Wanninger J and Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011; 17: 2801-2811."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"Tilg","year":"2006","unstructured":"Tilg H and Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783.","journal-title":"Nat Rev Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"8536","DOI":"10.1073\/pnas.97.15.8536","article-title":"Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets","volume":"97","author":"Kakuma","year":"2000","unstructured":"Kakuma T, Lee Y, Higa M, Wang Zw, Pan W, Shimomura I and Unger RH. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A 2000; 97: 8536-8541.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Farrell GC and Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 Suppl 1: S99-S112.","DOI":"10.1002\/hep.20973"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Day CP and James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842-845.","DOI":"10.1016\/S0016-5085(98)70599-2"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2337\/db08-1220","article-title":"Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss","volume":"58","author":"Gregor","year":"2009","unstructured":"Gregor MF, Yang L, Fabbrini E, Mohammed BS, Eagon JC, Hotamisligil GS and Klein S. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009; 58: 693-700.","journal-title":"Diabetes"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1126\/science.1103160","article-title":"Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes","volume":"306","author":"Ozcan","year":"2004","unstructured":"Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH and Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461.","journal-title":"Science"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/hep.22183","article-title":"The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity","volume":"47","author":"Li","year":"2008","unstructured":"Li Z, Berk M, McIntyre TM, Gores GJ and Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008; 47: 1495-1503.","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.clinbiochem.2012.03.024","article-title":"Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation","volume":"45","author":"Grattagliano","year":"2012","unstructured":"Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ and Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation. Clin Biochem 2012; 45: 610-618.","journal-title":"Clin Biochem"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/j.1572-0241.2004.40009.x","article-title":"Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients","volume":"99","author":"Ribeiro","year":"2004","unstructured":"Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME and Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-1717.","journal-title":"Am J Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nm1166","article-title":"Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB","volume":"11","author":"Cai","year":"2005","unstructured":"Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J and Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190.","journal-title":"Nat Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jhep.2022.07.017","article-title":"MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM","volume":"77","author":"Tian","year":"2022","unstructured":"Tian C, Min X, Zhao Y, Wang Y, Wu X, Liu S, Dou W, Zhou T, Liu Y, Luo R, Li Z, Lui KO, Li Y, Zhou B and Ding Q. MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM. J Hepatol 2022; 77: 1491-1503.","journal-title":"J Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/j.1365-2265.2006.02527.x","article-title":"Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2006","unstructured":"Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L and Falezza G. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006; 64: 679-683.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt","year":"2010","unstructured":"Brunt EM and Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 5286-5296.","journal-title":"World J Gastroenterol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","article-title":"Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"18","author":"Takahashi","year":"2012","unstructured":"Takahashi Y, Soejima Y and Fukusato T. Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18: 2300-2308.","journal-title":"World J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z and Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67: 123-133.","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S and Bendtsen F. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389-397, e310.","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S and Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554.","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S and Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69: 896-904.","journal-title":"J Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1152\/japplphysiol.00071.2002","article-title":"Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle","volume":"92","author":"Park","year":"2002","unstructured":"Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS and Winder WW. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol (1985) 2002; 92: 2475-2482.","journal-title":"J Appl Physiol (1985)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cmet.2009.03.012","article-title":"AMPK: an emerging drug target for diabetes and the metabolic syndrome","volume":"9","author":"BB","year":"2009","unstructured":"Zhang BB, Zhou G and Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009; 9: 407-416.","journal-title":"Cell Metab"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Clin Liver Dis (Hoboken) 2018; 11: 81.","DOI":"10.1002\/cld.722"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","unstructured":"Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, Suman A, Orsak BK, Hecht J and Cusi K. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2019; 42: 1481-1488.","journal-title":"Diabetes Care"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/MOG.0b013e32834e7b4b","article-title":"Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression","volume":"28","author":"Corbin","year":"2012","unstructured":"Corbin KD and Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 2012; 28: 159-165.","journal-title":"Curr Opin Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Lee SJ, Kang JH, Iqbal W and Kwon OS. Proteomic analysis of mice fed methionine and choline deficient diet reveals marker proteins associated with steatohepatitis. PLoS One 2015; 10: e0120577.","DOI":"10.1371\/journal.pone.0120577"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.0959-9673.2006.00465.x","article-title":"Mouse models in non-alcoholic fatty liver disease and steatohepatitis research","volume":"87","author":"Anstee","year":"2006","unstructured":"Anstee QM and Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87: 1-16.","journal-title":"Int J Exp Pathol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.mri.2016.03.009","article-title":"Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice","volume":"34","author":"Yamada","year":"2016","unstructured":"Yamada T, Obata A, Kashiwagi Y, Rokugawa T, Matsushima S, Hamada T, Watabe H and Abe K. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice. Magn Reson Imaging 2016; 34: 724-729.","journal-title":"Magn Reson Imaging"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Machado MV, Michelotti GA, Xie G, Almeida Pereira T, Boursier J, Bohnic B, Guy CD and Diehl AM. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One 2015; 10: e0127991.","DOI":"10.1371\/journal.pone.0127991"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S0168-8278(03)00376-3","article-title":"Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis","volume":"39","author":"George","year":"2003","unstructured":"George J, Pera N, Phung N, Leclercq I, Yun Hou J and Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003; 39: 756-764.","journal-title":"J Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jhep.2008.03.026","article-title":"MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes","volume":"49","author":"Larter","year":"2008","unstructured":"Larter CZ, Yeh MM, Williams J, Bell-Anderson KS and Farrell GC. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol 2008; 49: 407-416.","journal-title":"J Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/ajcn\/79.3.502","article-title":"Model of nonalcoholic steatohepatitis","volume":"79","author":"Lieber","year":"2004","unstructured":"Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A and DeCarli LM. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004; 79: 502-509.","journal-title":"Am J Clin Nutr"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4162\/nrp.2015.9.4.350","article-title":"Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets","volume":"9","author":"Fakhoury-Sayegh","year":"2015","unstructured":"Fakhoury-Sayegh N, Trak-Smayra V, Khazzaka A, Esseily F, Obeid O, Lahoud-Zouein M and Younes H. Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets. Nutr Res Pract 2015; 9: 350-357.","journal-title":"Nutr Res Pract"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-981-10-8684-7_11","article-title":"Animal models of non-alcoholic fatty liver diseases and its associated liver cancer","volume":"1061","author":"JKC","year":"2018","unstructured":"Lau JKC, Zhang X and Yu J. Animal models of non-alcoholic fatty liver diseases and its associated liver cancer. Adv Exp Med Biol 2018; 1061: 139-147.","journal-title":"Adv Exp Med Biol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","article-title":"Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis","volume":"4","author":"Mari","year":"2006","unstructured":"Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC and Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4: 185-198.","journal-title":"Cell Metab"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/hep.25789","article-title":"Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis","volume":"57","author":"Savard","year":"2013","unstructured":"Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS and Ioannou GN. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013; 57: 81-92.","journal-title":"Hepatology"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ejphar.2017.11.021","article-title":"Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model","volume":"818","author":"Briand","year":"2018","unstructured":"Briand F, Brousseau E, Quinsat M, Burcelin R and Sulpice T. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model. Eur J Pharmacol 2018; 818: 449-456.","journal-title":"Eur J Pharmacol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/hep.21874","article-title":"Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet","volume":"46","author":"Matsuzawa","year":"2007","unstructured":"Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K and Kaneko S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007; 46: 1392-1403.","journal-title":"Hepatology"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3748\/wjg.v19.i8.1166","article-title":"Fructose as a key player in the development of fatty liver disease","volume":"19","author":"Basaranoglu","year":"2013","unstructured":"Basaranoglu M, Basaranoglu G, Sabuncu T and Senturk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19: 1166-1172.","journal-title":"World J Gastroenterol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jnutbio.2011.09.006","article-title":"The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease","volume":"23","author":"Nomura","year":"2012","unstructured":"Nomura K and Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012; 23: 203-208.","journal-title":"J Nutr Biochem"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"MF","year":"2010","unstructured":"Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ and Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1961-1971.","journal-title":"Hepatology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jhep.2008.02.011","article-title":"Fructose consumption as a risk factor for non-alcoholic fatty liver disease","volume":"48","author":"Ouyang","year":"2008","unstructured":"Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ and Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-999.","journal-title":"J Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00335-014-9521-3","article-title":"Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse","volume":"25","author":"Riordan","year":"2014","unstructured":"Riordan JD and Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014; 25: 473-486.","journal-title":"Mamm Genome"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ijms18081649","article-title":"Adipokines and non-alcoholic fatty liver disease: multiple interactions","volume":"18","author":"Adolph","year":"2017","unstructured":"Adolph TE, Grander C, Grabherr F and Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci 2017; 18: 1649.","journal-title":"Int J Mol Sci"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2613.2011.00793.x","article-title":"Pathology of the liver in obese and diabetic ob\/ob and db\/db mice fed a standard or high-calorie diet","volume":"92","author":"Trak-Smayra","year":"2011","unstructured":"Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V and Fromenty B. Pathology of the liver in obese and diabetic ob\/ob and db\/db mice fed a standard or high-calorie diet. Int J Exp Pathol 2011; 92: 413-421.","journal-title":"Int J Exp Pathol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S0168-8278(02)00102-2","article-title":"Leptin is essential for the hepatic fibrogenic response to chronic liver injury","volume":"37","author":"Leclercq","year":"2002","unstructured":"Leclercq IA, Farrell GC, Schriemer R and Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-213.","journal-title":"J Hepatol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s40168-021-01097-8","article-title":"Novel insights into the genetically obese (ob\/ob) and diabetic (db\/db) mice: two sides of the same coin","volume":"9","author":"Suriano","year":"2021","unstructured":"Suriano F, Vieira-Silva S, Falony G, Roumain M, Paquot A, Pelicaen R, Regnier M, Delzenne NM, Raes J, Muccioli GG, Van Hul M and Cani PD. Novel insights into the genetically obese (ob\/ob) and diabetic (db\/db) mice: two sides of the same coin. Microbiome 2021; 9: 147.","journal-title":"Microbiome"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1590\/S0004-27302010000800005","article-title":"Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy","volume":"54","author":"Paz-Filho","year":"2010","unstructured":"Paz-Filho G, Mastronardi C, Delibasi T, Wong ML and Licinio J. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arq Bras Endocrinol Metabol 2010; 54: 690-697.","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.2337\/diabetes.54.5.1581","article-title":"Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes","volume":"54","author":"Hearn","year":"2005","unstructured":"Hearn T, Spalluto C, Phillips VJ, Renforth GL, Copin N, Hanley NA and Wilson DI. Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. Diabetes 2005; 54: 1581-1587.","journal-title":"Diabetes"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1210\/me.2005-0494","article-title":"Fat aussie--a new Alstrom syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis","volume":"20","author":"Arsov","year":"2006","unstructured":"Arsov T, Silva DG, O’Bryan MK, Sainsbury A, Lee NJ, Kennedy C, Manji SS, Nelms K, Liu C, Vinuesa CG, de Kretser DM, Goodnow CC and Petrovsky N. Fat aussie--a new Alstrom syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol Endocrinol 2006; 20: 1610-1622.","journal-title":"Mol Endocrinol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/liv.12335","article-title":"Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype","volume":"34","author":"Farrell","year":"2014","unstructured":"Farrell GC, Mridha AR, Yeh MM, Arsov T, Van Rooyen DM, Brooling J, Nguyen T, Heydet D, Delghingaro-Augusto V, Nolan CJ, Shackel NA, McLennan SV, Teoh NC and Larter CZ. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype. Liver Int 2014; 34: 1084-1093.","journal-title":"Liver Int"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.aohep.2022.100780","article-title":"Activation of the NLRP3 inflammasome by CCl(4) exacerbates hepatopathogenic diet-induced experimental NASH","volume":"28","author":"Vargas-Pozada","year":"2023","unstructured":"Vargas-Pozada EE, Ramos-Tovar E, Rodriguez-Callejas JD, Cardoso-Lezama I, Galindo-Gomez S, Gil-Becerril K, Vasquez-Garzon VR, Arellanes-Robledo J, Tsutsumi V, Villa-Trevino S and Muriel P. Activation of the NLRP3 inflammasome by CCl(4) exacerbates hepatopathogenic diet-induced experimental NASH. Ann Hepatol 2023; 28: 100780.","journal-title":"Ann Hepatol"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM and Whitington PF. Obese and diabetic db\/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1035-43.","DOI":"10.1152\/ajpgi.00199.2004"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3748\/wjg.v22.i8.2512","article-title":"Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice","volume":"22","author":"Yamamoto","year":"2016","unstructured":"Yamamoto T, Nakade Y, Yamauchi T, Kobayashi Y, Ishii N, Ohashi T, Ito K, Sato K, Fukuzawa Y and Yoneda M. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J Gastroenterol 2016; 22: 2512-2523.","journal-title":"World J Gastroenterol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.7150\/thno.21400","article-title":"Pro-inflammatory CXCR3 impairs mitochondrial function in experimental non-alcoholic steatohepatitis","volume":"7","author":"Du","year":"2017","unstructured":"Du J, Zhang X, Han J, Man K, Zhang Y, Chu ES, Nan Y and Yu J. Pro-inflammatory CXCR3 impairs mitochondrial function in experimental non-alcoholic steatohepatitis. Theranostics 2017; 7: 4192-4203.","journal-title":"Theranostics"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/2\/ajtr0154025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:08Z","timestamp":1766022728000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/2\/ajtr0154025.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":72,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/kmsa5983","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}